Toronto · Independent Shariah screening · Screened October 1, 2026

Screened October 1, 2026 · TSX: CRDL (also NASDAQ: CRDL) · audited FY2025 financials + Q2 2026 balance sheet (June 30, 2026) + market data October 2026

Debt ÷ market cap 0.04% / 33%

Cardiol Therapeutics Inc.

CRDL · TSX · Healthcare

FAIL

Is Cardiol Therapeutics (CRDL) halal?

Cardiol Therapeutics (TSX: CRDL), the Oakville biotech developing CBD-based heart drugs, gets a FAIL: its entire drug pipeline is cannabidiol (CBD)-based - CardiolRx in Phase III for recurrent pericarditis and Phase II for acute myocarditis, plus CRD-38 for heart failure - which fails the business gate under this site's convention. Debt is negligible at about C$107k (~0.04% of a ~C$288M market cap).

Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.

The two-gate Shariah screen

Every screener on this site runs the same two gates: first, the business must be halal (no conventional insurance, banking, alcohol, gambling, weapons manufacturing, and the like); second, the financial ratios must clear (debt under roughly 33% of market cap, non-compliant income under roughly 5%).

Gate one: the business — FAILED

Cardiol Therapeutics Inc. (TSX: CRDL; NASDAQ: CRDL) is a clinical-stage life sciences company headquartered in Oakville, Ontario, focused on anti-inflammatory and anti-fibrotic therapies for heart disease. Its therapeutic approach centers on pharmaceutically manufactured cannabidiol formulations: the lead candidate CardiolRx is an oral cannabidiol solution in the Phase III MAVERIC trial for recurrent pericarditis and the Phase II ARCHER trial for acute myocarditis, and CRD-38 is a proprietary subcutaneous cannabidiol formulation for heart failure. Cannabidiol (CBD) is a cannabis-plant-derived compound. The company describes its drugs as pharmaceutical and its trials are FDA-authorized, but the core business is a cannabis-derived compound, and this site flags cannabis-related core business under the business gate - consistent with its earlier cannabis and pharma-cannabinoid screeners (Aurora Cannabis, Cronos, Curaleaf, MediPharm Labs), where even pharmaceutical-grade, regulated-channel cannabinoid activity failed the gate. The business gate fails. Facts only, no fatwa.

Gate two: the ratios — moot (debt passes)

The debt gate passes with room to spare. Q2 2026 figures show total debt of about C$107k - lease liabilities only (about C$41.31k short-term and C$65.72k long-term) - against a market capitalization of about C$288M (October 2026), about 0.04%, far under the ~33% ceiling. Income: Cardiol is pre-revenue with nil sales; its audited 2025 financial statements disclose a separate "interest earned on cash and cash equivalents" line of C$726,401 for 2025 (C$1,193,342 in 2024), effectively the company's only income, so no clean 5%-ceiling ratio can be computed against zero revenue - reported as unverifiable as a ratio, and moot given the decisive business-gate FAIL. All figures recomputed from the cited sources; Cardiol reports in Canadian dollars.

What other screeners say

No public Zoya, Musaffa or ShariaPortfolio coverage was found for Cardiol Therapeutics (CRDL) as of October 2026: no public Zoya page is indexed for the ticker, site-scoped Musaffa searches returned nothing, and ShariaPortfolio publishes no public per-stock screening pages for it. The FAIL recorded here rests on the company's own disclosures.

The bottom line

Cardiol Therapeutics (CRDL) is a FAIL under this site's AAOIFI-style screening: the business gate fails because the clinical-stage company's entire pipeline is cannabidiol-based - CardiolRx, a pharmaceutically manufactured oral cannabidiol solution in Phase III for recurrent pericarditis and Phase II for acute myocarditis, and CRD-38, a subcutaneous cannabidiol formulation for heart failure - and cannabis-derived core business is flagged under this site's convention, consistent with its cannabis and pharma-cannabinoid screeners. The debt gate passes: about C$107k of lease-only debt is about 0.04% of a ~C$288M market cap. Interest income is separately disclosed (C$726,401 in audited 2025) against nil revenue, so no 5%-ceiling ratio is published - moot. No public Zoya, Musaffa or ShariaPortfolio rating was found for this ticker as of October 2026. As with every screener here, this is a rules-based screening of published figures, not a religious ruling - consult a qualified scholar for personal guidance.

BDS screen

Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.

No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).

Moral screen

Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.

Israeli military business
No findings published.
US military business
No findings published.
Weapons manufacturing & arms trade
No findings published.

Halal alternatives in this sector

CRDL did not pass the screen. These companies in the same sector passed:

Sources

Frequently asked questions

Is Cardiol Therapeutics stock halal?

Based on this screener's AAOIFI-style checks, Cardiol fails on the business gate: the clinical-stage company's entire drug pipeline is cannabidiol (CBD)-based - CardiolRx, an oral cannabidiol solution in Phase III for recurrent pericarditis and Phase II for acute myocarditis, plus CRD-38, a subcutaneous cannabidiol formulation for heart failure. CBD is a cannabis-derived compound, and cannabis-related activity is flagged under this site's convention (consistent with its cannabis/pharma-cannabinoid screeners). Debt is negligible (~0.04% of market cap). This is a screening result, not investment advice or a religious ruling.

How does Cardiol Therapeutics score on the debt ratio?

The debt gate passes: total debt is about C$107k (lease liabilities only, per Q2 2026 figures) against a market capitalization of about C$288M (October 2026), about 0.04% - far under the ~33% ceiling. This gate is moot given the business-gate FAIL.

Why does Cardiol Therapeutics fail the business gate?

Cardiol's whole business is cannabidiol-based: its lead candidate CardiolRx is a pharmaceutically manufactured oral cannabidiol solution in the Phase III MAVERIC trial for recurrent pericarditis and the Phase II ARCHER trial for acute myocarditis, and CRD-38 is a subcutaneous cannabidiol formulation for heart failure. Cannabidiol is a cannabis-plant-derived compound. This site flags cannabis-related core business under its business gate (as it did for cannabis and pharma-cannabinoid companies) - the medicinal setting does not change the screening treatment here.

What is Cardiol Therapeutics' interest income to revenue ratio?

Not computable as a clean ratio: Cardiol is pre-revenue (nil sales), and its audited 2025 financial statements disclose a separate interest-earned line of C$726,401 for 2025 (C$1,193,342 in 2024) - effectively the company's only income. Per the honesty rule no 5%-ceiling ratio is published against zero revenue; this gate is moot given the decisive business-gate FAIL.

Do Zoya, Musaffa, or ShariaPortfolio rate Cardiol Therapeutics?

No public coverage was found as of October 2026: no public Zoya page is indexed for the ticker, site-scoped Musaffa searches returned nothing, and ShariaPortfolio publishes no public per-stock screening pages for it. The FAIL recorded here rests on the company's own disclosures.